Wegovy is a GLP-1 receptor agonists and a Brand name for the drug known as Semaglutide. It helps with weight loss by mirroring the function of GLP-1 (glucagon-like-peptide-1), a hormone that is naturally occurring in the body. In a brief summary GLP-1 agonists promote the release of insulin to help regulate blood sugar after meals, slow gastric emptying, and reduce appetite.

Mounjaro is a Glucose Dependent Insulinotropic Polypeptide (GIP) AND a Glucagon-Like Peptide (GLP-1) Receptor agonist. It is the brand name for the drug known as Tirzepatide. Instead of working on only one naturally occurring hormone in the body, like Wegovy (GLP-1), it works on two (GLP-1 and GIP) hormones in the body to help promote weight loss and improve blood sugar. In summary Mounjaro not only promotes the release of insulin like Wegovy but also reduces glucagon levels to help regulate blood sugar before and after meals, slows gastric emptying, and reduces appetite.

• Insulin is a natural occurring hormone that reduces blood sugar levels.
• Glucagon is a natural occurring hormone that increases blood sugar.

The main differences between the two medications include:

• Hormones influenced: Mounjaro increases insulin and decreases glucagon. Wegovy increases insulin.
• Dosing strengths: Mounjaro is available up to 15mg and Wegovy is available up to 2.4mg.
• FDA approval: Mounjaro is FDA approved for type 2 diabetes and used off label for weight loss. Wegovy is FDA approved for the treatment of overweight and obesity diagnosis.
• Average weight loss: Some adults taking Mounjaro achieve up to 22% total body weight loss. 1 in 3 adults taking Wegovy achieve 20% total body weight loss.

Both medications are to be used in conjunction with diet and exercise to achieve desired results. Please contact our office to find out how we can help you to get started on your weight loss journey!